ReviewJournal of medical virology2021
The impact of the SARS-CoV-2 infection, with special reference to the hematological setting.
Review in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Prevalence, Features and Degree of Association of Oral Lesions in COVID-19: A Systematic Review of Systematic Reviews.International journal of environmental research and public health · 2022Pooled it
- SARS-CoV-2 infection affects the lower urinary tract and male genital system: A systematic review.Journal of medical virology · 2021Pooled it
- Fertility-sparing surgery: a hopeful strategy for young women with cancer.Journal of medicine and life · 2023Review
- Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.Healthcare (Basel, Switzerland) · 2023Review
- Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection.Pathogens (Basel, Switzerland) · 2023Article
- Article
- Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19.Pathogens (Basel, Switzerland) · 2022Review
- The Impact of Direct Oral Anticoagulant Prophylaxis for Thromboembolism in Thrombophilic Patients Undergoing Abdominoplastic Surgery.Healthcare (Basel, Switzerland) · 2022Article
- Review
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients.Journal of medical virology · 2021Article
- Chronic Chest Pain Control after Trans-Thoracic Biopsy in Mediastinal Lymphomas.Healthcare (Basel, Switzerland) · 2021Article
- Primary Extra-Nodal DLBCL of Glands: Our Experiences outside Guidelines of Treatment.Healthcare (Basel, Switzerland) · 2021Article
- Management of SARS-CoV-2 pneumonia.Journal of medical virology · 2021Review
- The outcome of COVID-19 in patients with hematological malignancy.Journal of medical virology · 2021Article
- How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report.Healthcare (Basel, Switzerland) · 2021Article
- The impact of the SARS-CoV-2 infection, with special reference to the hematological setting.Journal of medical virology · 2021Review
- Safeguarding COVID-19 and cancer management: drug design and therapeutic approach.Open research Europe · 2021Review
- Dermatological Considerations in the Diagnosis and Treatment of Marginal Zone Lymphomas.Clinical, cosmetic and investigational dermatology · 2021Review
- Clinical Presentation of COVID-19: Case Series and Review of the Literature.International journal of environmental research and public health · 2020Review
- All-in-One Spinal Cord Stimulation in Lymphoproliferative Diseases.Frontiers in neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a disease known from a few months, caused by a recently arisen virus and, consequently, it is little known. The disease has a benign course in most infected subjects (children and young adults), is often symptomatic in adults over the age of 50 and often serious and life threatening in people with comorbidities and the elderly. The few data published on coronavirus disease-2019 (COVID-19) in the blood-oncology field report a serious clinical presentation, a serious course of the disease, and a high mortality rate, as has also been reported for other cancer contexts. The current strategy for treating patients with SARS-CoV-2 includes antivirals that are effective against other viral infections and drugs that can moderate the cytokine storm. There is no specific vaccine and consequently all possible precautions must be taken to prevent SARS-CoV-2 infection in the areas of oncology, oncohematology, and bone marrow transplantation. In this reviewer's article, we report the information currently available on SARS-CoV-2 infection to help young doctors and hematologists to successfully manage patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.